Ind-Swift Limited (INDSWFTLTD.BO)
INR 13.05
(-0.84%)
INR 13.05
(-0.84%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.06 Billion INR | -7.09% |
| 2022 | 1.14 Billion INR | -24.27% |
| 2021 | 618.21 Million INR | 14.01% |
| 2020 | 469.62 Million INR | 32.13% |
| 2019 | 521.2 Million INR | 115.9% |
| 2018 | 174.02 Million INR | -26.23% |
| 2017 | -72.83 Million INR | 169.19% |
| 2016 | -3.12 Billion INR | 66.75% |
| 2015 | -1.42 Billion INR | -108.13% |
| 2014 | -682.45 Million INR | -1518.49% |
| 2013 | -160.57 Million INR | -316.96% |
| 2012 | -109.85 Million INR | 0.0% |
| 2010 | 1.31 Billion INR | 41.19% |
| 2009 | 934.63 Million INR | 7.7% |
| 2008 | 867.67 Million INR | 14.87% |
| 2007 | 755.47 Million INR | 48.56% |
| 2006 | 508.52 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 32.2 Million INR | -29.35% |
| 2023 FY | - INR | -7.09% |
| 2023 Q4 | 144.86 Million INR | 222.82% |
| 2023 Q3 | 44.87 Million INR | -68.61% |
| 2023 Q2 | 142.93 Million INR | -40.51% |
| 2023 Q1 | 240.28 Million INR | 91.29% |
| 2022 Q4 | 125.61 Million INR | -40.46% |
| 2022 Q3 | 210.95 Million INR | 76.9% |
| 2022 Q2 | 119.25 Million INR | 79.78% |
| 2022 Q1 | 66.33 Million INR | -65.26% |
| 2022 FY | - INR | -24.27% |
| 2021 Q3 | 153.63 Million INR | -19.38% |
| 2021 Q1 | 174.19 Million INR | 44.08% |
| 2021 Q2 | 190.56 Million INR | 9.4% |
| 2021 FY | - INR | 14.01% |
| 2021 Q4 | 190.92 Million INR | 24.27% |
| 2020 FY | - INR | 32.13% |
| 2020 Q1 | 124.64 Million INR | -17.47% |
| 2020 Q2 | 170.37 Million INR | 36.69% |
| 2020 Q3 | 188.86 Million INR | 10.85% |
| 2020 Q4 | 120.9 Million INR | -35.98% |
| 2019 FY | - INR | 115.9% |
| 2019 Q3 | 153.51 Million INR | 78.12% |
| 2019 Q4 | 151.01 Million INR | -1.62% |
| 2019 Q1 | 66.98 Million INR | 976.35% |
| 2019 Q2 | 86.18 Million INR | 28.67% |
| 2018 FY | - INR | -26.23% |
| 2018 Q3 | 4.87 Million INR | -89.15% |
| 2018 Q4 | 6.22 Million INR | 27.57% |
| 2018 Q2 | 44.96 Million INR | -70.07% |
| 2018 Q1 | 150.25 Million INR | -5.85% |
| 2017 Q4 | 159.59 Million INR | 67.34% |
| 2017 Q1 | -29.28 Million INR | 95.96% |
| 2017 FY | - INR | 169.19% |
| 2017 Q3 | 95.37 Million INR | 0.0% |
| 2016 Q1 | -123.69 Million INR | 88.45% |
| 2016 Q3 | -1.73 Billion INR | -212.91% |
| 2016 Q2 | -553.56 Million INR | -347.52% |
| 2016 Q4 | -725.11 Million INR | 58.14% |
| 2016 FY | - INR | 66.75% |
| 2015 FY | - INR | -108.13% |
| 2015 Q2 | -75.66 Million INR | 49.1% |
| 2015 Q4 | -1.07 Billion INR | -742.49% |
| 2015 Q3 | -127.07 Million INR | -67.94% |
| 2015 Q1 | -148.65 Million INR | 53.96% |
| 2014 Q2 | -36.78 Million INR | -7.15% |
| 2014 FY | - INR | -1518.49% |
| 2014 Q4 | -322.88 Million INR | 0.5% |
| 2014 Q3 | -324.5 Million INR | -782.14% |
| 2014 Q1 | -34.33 Million INR | -285.0% |
| 2013 Q2 | -133.75 Million INR | -34.23% |
| 2013 FY | - INR | -316.96% |
| 2013 Q1 | -99.64 Million INR | 16.37% |
| 2013 Q3 | -13.12 Million INR | 90.19% |
| 2013 Q4 | 18.55 Million INR | 241.43% |
| 2012 Q4 | -119.14 Million INR | -57.08% |
| 2012 FY | - INR | 0.0% |
| 2012 Q1 | - INR | 0.0% |
| 2012 Q2 | 98.46 Million INR | 0.0% |
| 2012 Q3 | -75.85 Million INR | -177.03% |
| 2010 FY | - INR | 41.19% |
| 2009 FY | - INR | 7.7% |
| 2008 FY | - INR | 14.87% |
| 2007 FY | - INR | 48.56% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.23% |
| NATCO Pharma Limited | 18.79 Billion INR | 94.333% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 77.228% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -147.531% |
| Achyut Healthcare Limited | 524 Thousand INR | -203156.87% |
| Ajanta Pharma Limited | 12.56 Billion INR | 91.524% |
| Alkem Laboratories Limited | 24.19 Billion INR | 95.598% |
| Alpa Laboratories Limited | 86.12 Million INR | -1136.623% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 88.925% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 54.809% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 98.276% |
| Bajaj HealthCare Limited | 444.51 Million INR | -139.601% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 27.989% |
| Brooks Laboratories Limited | 41.72 Million INR | -2452.401% |
| Divi's Laboratories Limited | 25.43 Billion INR | 95.812% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.793% |
| Eris Lifesciences Limited | 6.98 Billion INR | 84.755% |
| FDC Limited | 4.4 Billion INR | 75.803% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 90.611% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 84.481% |
| Granules India Limited | 8.6 Billion INR | 87.621% |
| Gufic Biosciences Limited | 1.48 Billion INR | 28.06% |
| Hester Biosciences Limited | 539.47 Million INR | -97.428% |
| Indoco Remedies Limited | 2.64 Billion INR | 59.764% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 84.478% |
| Ipca Laboratories Limited | 13.29 Billion INR | 91.992% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -229.273% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1387.447% |
| Lasa Supergenerics Limited | -65.08 Million INR | 1736.549% |
| Laurus Labs Limited | 8 Billion INR | 86.697% |
| Lupin Limited | 36.96 Billion INR | 97.119% |
| Mankind Pharma Limited | 28.09 Billion INR | 96.209% |
| Medicamen Biotech Limited | 245.66 Million INR | -333.553% |
| Medico Remedies Limited | 150.37 Million INR | -608.259% |
| Megasoft Limited | 284.73 Million INR | -274.06% |
| Piramal Pharma Limited | 13.05 Billion INR | 91.842% |
| RPG Life Sciences Limited | 1.28 Billion INR | 16.889% |
| Sigachi Industries Limited | 883.39 Million INR | -20.565% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 128.544% |
| Unichem Laboratories Limited | 742.35 Million INR | -43.471% |
| Wanbury Limited | 985.49 Million INR | -8.075% |
| Windlas Biotech Limited | 781.72 Million INR | -36.246% |
| ZIM Laboratories Limited | 462.09 Million INR | -130.485% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 98.106% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 64.667% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -56.045% |
| Bal Pharma Limited | 345.59 Million INR | -208.186% |
| Strides Pharma Science Limited | 3.76 Billion INR | 71.709% |
| Venus Remedies Limited | 711.8 Million INR | -49.63% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 72.756% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 31.892% |
| Shilpa Medicare Limited | 2.58 Billion INR | 58.846% |
| Aarti Drugs Limited | 3.24 Billion INR | 67.215% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 59.14% |
| Suven Life Sciences Limited | -992.78 Million INR | 207.281% |
| Valiant Laboratories Limited | 12.73 Million INR | -8260.672% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 88.59% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 137.743% |
| Themis Medicare Limited | 562.6 Million INR | -89.309% |
| Hikal Limited | 2.69 Billion INR | 60.439% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 96.958% |
| Sequent Scientific Limited | 549.8 Million INR | -93.719% |
| Novartis India Limited | 1.26 Billion INR | 16.09% |
| Wockhardt Limited | 1.08 Billion INR | 1.383% |
| Jubilant Pharmova Limited | 8 Billion INR | 86.697% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -8053.927% |
| Neuland Laboratories Limited | 4.74 Billion INR | 77.569% |
| Morepen Laboratories Limited | 1.72 Billion INR | 38.291% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -270.554% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -508.797% |